下一代口腔管理:将冷大气等离子体 (CAP) 与基于纳米凝的药物集成,以调节炎症
Yanfen Zheng1, Ziqi Zhuang2, Renwu Zhou3
1Xiamen Key Laboratory of Stomatological Disease Diagnosis and Treatment, Department of Pharmacy, Stomatological Hospital of Xiamen Medical College, Xiamen, 361008, China.
Advanced healthcare materials
|February 4, 2025
概括
一种新的冷大气等离子体 (CAP) 疗法,GCN,通过加速愈合和调节免疫反应,有效治疗口腔. 这种创新的治疗方法在临床前模型中显示出优异的结果,与传统方法相比.
科学领域:
- 生物医学工程 生物医学工程
- 血医学是一种血医学.
- 再生医学是一种再生医学.
背景情况:
- 口腔会影响成年人口的很大一部分,导致营养不良等并发症,特别是在弱势群体中.
- 目前用于口腔的治疗方法通常是无效的,原因是口腔环境中的快速清除.
- 了解口腔愈的分子机制对于开发先进疗法至关重要.
研究的目的:
- 调查冷大气等离子体 (CAP) 在治疗口腔的疗效,并阐明其分子机制.
- 开发和评估一种新的粘粘性纳米凝系统 (GCN) 与CAP相结合,用于增强口腔治疗.
- 将基于CAP的治疗方法的治疗效果与传统方法和未经处理的对照进行比较.
主要方法:
- 开发一种新型的三维 (3D) 多微孔CAP装置,与含有葡萄糖氧化酶 (GOx) 和催化酶 (CAT) (GCN) 的纳米凝相结合.
- 在老鼠模型中使用乙酸诱导口腔.
- 评估愈合率,免疫反应调节和表皮生长因子受体 (EGFR) 激活.
- 在实验室验证使用人类牙纤维细胞 (HGF) 和人类牙周带干干细胞 (PDLSC).
主要成果:
- 单独使用CAP和CAP+GCN组合都显著加快了与对照组和西瓜 (WF) 相比,口腔的愈合.
- CAP+GCN疗法调节了免疫反应,并激活了EGFR信号通路.
- CAP+GCN组合增强了纤维细胞的生成,并通过增强的细胞透性和纳米粒子吸收,改善了组织粘附.
- CAP预处理改善了纳米粒子吸收和组织粘附.
结论:
- 基于CAP的新型治疗 (CAP+GCN) 显示了加速口腔愈合和改善治疗结果的巨大潜力.
- CAP+GCN疗法为治疗口腔提供了一种优越,安全和生物相容的方法,其性能优于传统治疗方法.
- 这项研究在临床前模型中验证了CAP和GCN的疗效和安全性,为临床转化铺平了道路.
相关概念视频
Peptic Ulcer Disease IV: Management
60
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
60
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
329
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
329


